Characterizing the thrombotic spectrum and clinical phenotypes of tranexamic acid-associated adverse events: a pharmacovigilance study based on the FAERS database

The Sticky Situation: When Blood Clotting Goes Too Far

Imagine your body is a bustling city where blood is the traffic. Sometimes, an accident happens—a cut or a scrape—and the city needs to slam on the brakes to stop the bleeding. It builds a temporary roadblock, a clot, to patch the hole. Usually, once the road is fixed, the city's cleanup crew (enzymes called plasmin) comes along to dissolve the roadblock so traffic can flow again. But what if you gave the cleanup crew a "Do Not Disturb" sign? That's essentially what a drug called Tranexamic Acid (TXA) does. It's a super-hero for stopping bleeding, widely used in surgeries, trauma, and heavy periods to keep the "roadblocks" from dissolving too soon.

However, every superhero has a potential side effect. If you tell the cleanup crew to stand down too well, or in the wrong place, those roadblocks might stick around when they shouldn't. They could clog up the main highways (arteries) or the slower backstreets (veins), causing traffic jams that turn into serious accidents like strokes or heart attacks. Scientists have long wondered: Is TXA safe, or does it accidentally turn a life-saving patch into a dangerous clog? This question is the engine behind a new study that dug into a massive digital filing cabinet of medical reports to see exactly what kind of "traffic jams" happen when people take this drug.

The Big Dig: What the Study Found

Researchers decided to take a giant magnifying glass to the FDA's Adverse Event Reporting System (FAERS), a giant database where doctors and patients send in stories about weird or scary things that happen after taking medicine. They looked at reports from 2004 all the way up to the first quarter of 2026. Their mission? To find every single story where someone took TXA and then developed a blood clot. They didn't just look for "clots" in general; they wanted to know where the clots were, who got them, and what else those people were taking at the time.

After sifting through the data, they found 515 cases where TXA was linked to a thrombotic event (a blood clot). They sorted these 515 stories into four main neighborhoods of the body:

1. Venous Thromboembolism (VTE): Clots in the veins (like deep vein thrombosis or pulmonary embolism).
2. Arterial Thrombosis: Clots in the arteries (like heart attacks).
3. Cerebrovascular Thrombosis: Clots in the brain's blood vessels (strokes).
4. Intracardiac/Systemic Thrombosis: Clots inside the heart or other systemic areas.

Here is the twist: VTE was the big boss. It was the most common type of clot found, and it was also the most dangerous, leading to the highest number of deaths and life-threatening situations. If you look at a bubble chart of the findings, the bubbles for "Pulmonary Embolism" and "Deep Vein Thrombosis" are huge.

But the story gets more interesting when you look at the other types. The study found that Cerebrovascular thrombosis (brain clots) had a very different personality. These didn't happen mostly to older people, as you might expect with strokes. Instead, they showed up frequently in young women (ages 18–44). The study suggests this isn't because the drug suddenly makes young brains fragile, but because young women are the ones most often prescribed TXA for heavy periods or postpartum bleeding, and one specific type of brain clot (cerebral venous sinus thrombosis) is known to be more common in young women anyway.

Another fascinating discovery was about Intracardiac/Systemic thrombosis (clots in the heart or major vessels). When the researchers looked at what other drugs these patients were taking, they found a very specific "recipe." These patients were almost always taking a specific group of anesthesia drugs: lidocaine, fentanyl, midazolam, and propofol. The study suggests this isn't because these drugs cause the clots on their own, but rather that they are the "sidekicks" used during major surgeries or heart procedures where these clots are most likely to happen. It's like finding that every time a specific type of car crash happens, everyone in the car was wearing a specific brand of helmet; the helmet didn't cause the crash, but it tells you exactly what kind of driving was going on.

The Verdict: A Mixed Bag of Risks

The study didn't find that TXA is a villain that causes heart attacks in everyone. In fact, the data showed that common events like heart attacks (myocardial infarction) had a relatively weak "signal" compared to the drug, meaning they weren't reported as disproportionately often as other issues. However, the study did find that rare, specific types of clots had incredibly strong signals. For example, ovarian vein thrombosis and cerebral venous sinus thrombosis had massive reporting odds ratios (numbers that show how much more likely these events were reported with TXA than without). One rare event, ovarian vein thrombosis, had a signal so strong it was off the charts (a ratio of 352.95), suggesting that while these events are rare, when they do happen with TXA, it's a very notable pattern.

The researchers also built a "severity score" to weigh how bad the outcomes were. They gave points for death (4 points), life-threatening events (3 points), disability (2 points), and hospitalization (1 point). VTE scored the highest, meaning it brings the heaviest clinical burden. Cerebrovascular thrombosis was a close second, not because it killed as many people, but because it left more people disabled and hospitalized for long periods.

What This Means for the Future

The authors are careful to say they haven't "proved" that TXA causes these clots in a direct, cause-and-effect way. The data comes from voluntary reports, which can be messy—people might report scary things more often than boring things, and we don't always know the full medical history of the patients. However, the study paints a clear picture: TXA-associated clots are not all the same. They have different faces, hit different groups of people, and happen in different clinical settings.

The main takeaway is that while TXA is a great tool for stopping bleeding, it carries a risk of creating "sticky" situations in the veins, especially in the lungs. It also hints that if a young woman gets a specific type of brain clot while on TXA, or if a patient gets a heart clot while under anesthesia with specific drugs, there might be a unique pattern at play. The study suggests that doctors need to be extra careful and perhaps do a better job of checking who is at high risk before handing out the "Do Not Disturb" sign to the body's cleanup crew. It's a reminder that in medicine, even the most helpful tools need to be used with a sharp eye on the details.